Form D · Biotechnology
Gain Therapeutics, Inc.
Bethesda, MD · CIK 0001819411
Offering snapshot reported Jul 30, 2020 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 48 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Jul 20, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 30, 2020 | Initial | $10,000,000 | No comparison | 48 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $800K
- Finders' fees
- $0
- Form D file number
- 021-372084
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Tribal Capital Markets, LLC | 38901 |
Source: Form D, filed Jul 30, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Marianne Bjordal | Director |
| Khalid Islam | Director |
| Lorenzo Leoni | Director |
| Eric I. Richman | Director, Executive |
| Jeffrey Riley | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4800 Hampden Lane Suite 200
Bethesda, MD, 20814
Bethesda, MD, 20814